Tag: SIRT
Delcath Systems announces publication of study comparing chemosaturation and SIRT
Delcath Systems, an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, have announced the publication of an...
Holmium-166 SIRT demonstrates safety and efficacy in the treatment of HCC
University Medical Center Utrecht (Utrecht, Netherlands) recently published the latest results from the HEPAR Primary study, which evaluated the safety and efficacy of Holmium-166...
Personalised dosimetry and inclusion in guidelines redraw SIRT use for HCC
Jon Bell (Manchester, UK) outlines the importance of standardisation of selective internal radiation therapy (SIRT) and how this rests on an advanced understanding of...
BSIR 2021: Interventional radiologists rev up on IR registry and build...
The British Society for Interventional Radiology (BSIR) has set up an interventional radiology (IR) registry to capture a glimpse of the scope, breadth and...
DOORwaY90 study launches: The first prospective, multicentre US-based trial for registration...
The US Food and Drug Administration (FDA) have approved the DOORwaY90 study, a trial evaluating the safety and efficacy of selective internal radiation therapy...
Personalised treatment planning “the future” of radioembolization, ECIO hears, in Y-90...
Personalised treatment selection and planning based on controlled dosimetry will lead to improvements in treatment accuracy. This is the conclusion presented by Marnix Lam...
QuiremScout shows superior predictive value to technetium 99m macroaggregated albumin during...
A recent study comparing holmium-166 (QuiremSpheres, from Terumo) to technetium-99m-macroaggregated albumin (99mTc-MAA) as a work up for selective internal radiation therapy (SIRT) has found...
SIRT approved for routine commissioning on the NHS
National Health Service (NHS) England have announced that selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) microspheres will now be routinely commissioned for NHS...
QuiremScout, the first and only product indicated for SIRT work-up, receives...
QuiremScout (Quirem Medical) has received CE mark, making it available for clinical centres throughout Europe. QuiremScout is designed to advance the SIRT (selective internal...
Lessons from randomised controlled trials utilising SIRT in liver cancer
A recent session at CIRSE 2018 sought to go beyond the headline findings from a number of recent randomised controlled trials (RCTs) in interventional...
Sirtex prefers US$1.4 billion CDH-CGP bid to Varian’s acquisition offer
Sirtex has announced entering into a binding scheme implementation deed with CDH Genetech (CDH) and China Grand Pharmaceuticals and Healthcare Holdings Limited (CGP). It...
Establishing the evidence base for SIRT in Interventional Oncology
Multidisciplinary oncology thought leaders discuss the personalisation of SIRT, new and recent evidence for the minimally invasive procedure over sorafenib in advanced HCC, the...
SIRT fails to extend survival in the SORAMIC study palliative cohort
The SORAMIC study, presented at The International Liver Congress, shows that the addition of selective internal radiation therapy (SIRT) to sorafenib in patients with...
MIM software receives US FDA 510(k) clearance for post-treatment dosimetry of...
Dosimetry, within the context of selective internal radiation therapy (SIRT) using Y-90 microspheres, is typically understood to be the measurement and calculation of the...
Terumo launches QuiremSpheres microspheres in Europe
Terumo has announced that it has launched QuiremSpheres microspheres in Europe on 18 September.
QuiremSpheres, the next generation of selective internal radiation therapy (SIRT) microspheres...
SIRveNIB abstract published by ASCO, to be presented on 4 June
SIRveNIB is an investigator-led Asia Pacific Primary Liver Cancer Study to be presented on 4 June 2017 at the American Society of Clinical Oncology...
REsect study shows SIRT makes metastatic colorectal cancer patients more likely...
Metastatic colorectal cancer patients treated first-line with SIR-spheres Y-90 resin microspheres more likely to become candidates for potentially curative liver surgery, the REsect study...
New data show SIRT does not prolong overall survival in metastatic...
The FOXFIRE, SIRFLOX and FOXFIRE Global randomised studies evaluated the efficacy of combining first-line chemotherapy for metastatic colorectal cancer with selective internal radiotherapy (SIRT)...
SIRT significantly better tolerated than sorafenib, but does not increase overall...
The 459-patient randomised controlled SARAH study shows that local treatments of advanced or inoperable hepatocellular carcinoma with selective internal radiation therapy (SIRT) did not...
New NCCN guidelines recommend SIRT for the treatment of metastatic colorectal...
Sirtex has announced that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network...
SIRT access “under threat” from commissioning through evaluation process
Selective internal radiation therapy (SIRT) has been available since December 2013 to a defined group of patients with liver metastases in England on the...
BTG and Mirada Medical announce CE mark certification for Simplicit90Y dosimetry...
BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy...
New ESMO biliary cancer guidelines indicate radioembolization as an option for...
New European Society of Medical Oncology (ESMO) biliary cancer guidelines indicate yttrium-90 (Y-90) therapy as an option for post-chemotherapy treatment of intrahepatic cholangiocarcinoma.
Sirtex has announced...
